Dr. Milton E Gibson, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1920 Whispering Pines Ct, Goshen, IN 46526 Phone: 574-286-0491 Fax: 574-291-8797 |
Dr. Farid Jalinous, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 S Main St Ste A, Goshen, IN 46526 Phone: 574-533-7476 |
Dr. Djavid Hadian, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 S Main St Ste A, Goshen, IN 46526 Phone: 574-533-7476 Fax: 574-533-7145 |
Dr. Mark L. Smucker, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1855 S Main St Ste A, Goshen, IN 46526 Phone: 574-533-7476 Fax: 574-533-7145 |
Sreenivas P Kamath, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 S Main St Ste A, Goshen, IN 46526 Phone: 574-533-7476 Fax: 574-533-7145 |
Blair Macphail, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 S Main St, Ste A, Goshen, IN 46526 Phone: 574-533-7476 |
News Archive
During a three-year period in seven metropolitan areas in the western United States, the emergency medical services system sent more than 85,000 injured patients to major trauma hospitals who didn't need to go there - costing the health care system more than $130 million per year, according to an Oregon Health & Science University study published today in the journal Health Affairs.
A Mayo Clinic-led study involving 3,276 patients has found that people with inflammatory bowel disease, Type 1 diabetes or blood clots may be at increased risk of developing rheumatoid arthritis.
The recent deaths of two high school football players illustrate the dangers of drinking too much water and sports drinks, according to Loyola University Medical Center sports medicine physician Dr. James Winger.
VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).
› Verified 5 days ago